New Study Supports Hitting MS Fast and Hard
Any DMT is better than noneThe study found that people with RRMS who were initially treated with a glatiramer acetate (Copaxone, Glatopa) or an interferon beta (Avonex, Betaferon, Extavia, Rebif) had a lower risk (12 percent) of progressing to secondary progressive MS (SPMS) than people who received no treatment (27 percent). Those who received fingolimod (Gilenya) also had a lower risk (7 percent versus 32 percent), as did natalizumab (Tysabri) (19 percent versus 38 percent) and alemtuzumab (Lemtrada) (10 percent versus 25 percent).
Treat MS quickly and effectivelyOne of the study’s lead authors, Tomas Kalincik, associate professor and head of the MS Service at The Royal Melbourne Hospital, said that the findings show how important it is to treat MS quickly and effectively. “People who converted from relapsing MS to secondary progressive MS experience gradual and mostly irreversible worsening of disability. Most of the therapies that we use to treat MS have no effect once people have converted to secondary progressive MS. This study shows us how important it is to treat relapsing MS early and pro-actively,” Kalincik said, according to a news release.
‘Wait and see’ isn’t the way to goConsider all of this information when you and your neurologist are making DMT decisions, especially if you’ve just recently been diagnosed. Then, IMHO, you should hit your MS as fast and hard as you can. You’re invited to follow my personal blog at www.themswire.com.
***Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Multiple Sclerosis News Today or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to multiple sclerosis.